Quest sees registration of dengue test kit in Brazil; Tribogenics closes $2.5M in funding;

> Quest Diagnostics ($DGX) reports that the Simplexa dengue molecular test kit developed by its Focus Diagnostics products business has been registered for distribution in Brazil. Quest release

> Tribogenics closes $2.5 million in funding from a network of global angel investors and Flywheel Ventures. The funds will be used to commercialize new technology that enables miniature low-cost X-ray sources for a wide range of applications, including scientific instruments, security screening and medical devices. Tribogenics release

> In-vitro specialist Protagen and Bayer HealthCare Pharmaceuticals announce a new collaboration project for the clinical validation of diagnostic biomarkers in endometriosis. Protagen release

> Bangalore's S3V Vascular Technologies is establishing a facility to manufacture and develop products in intervention cardiology, neurology, peripheral and endovascular treatments. Item

> Amp Orthopedics announces the start of a clinical trial in adults with mild-to-moderate knee osteoarthritis to determine the safety and effectiveness of the company's nonthermal pulsed radio frequency technology to alleviate pain. Amp release

> Breast cancer patients who undergo targeted radiation are almost twice as likely to need a mastectomy later as those who get a full course of the treatment, according to study data. Report

And Finally... Olympus introduces a new microscope designed to deliver vivid 3-D images of structures 8mm deep. Item

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.